Up to 5% of the US population has suffered anaphylaxis. Fatal outcome is rare, such that
even for people with known venom or food allergy, fatal anaphylaxis constitutes less than …

Abstract Background The European Academy of Allergy and Clinical Immunology (EAACI) is
in the process of developing the EAACI Guidelines on Allergen Immunotherapy (AIT) for the …

The availability of allergen molecules ('components') from several protein families has
advanced our understanding of immunoglobulin E (IgE)‐mediated responses and enabled …

Anaphylaxis is a clinical emergency, and all healthcare professionals should be familiar with
its recognition and acute and ongoing management. These guidelines have been prepared …

To establish the effectiveness of interventions for the acute and long‐term management of
anaphylaxis, seven databases were searched for systematic reviews, randomized controlled …

Background Component resolution recently identified distinct sensitization profiles in honey
bee venom (HBV) allergy, some of which were dominated by specific IgE to Api m 3 and/or …

Background Treatment failure during venom immunotherapy (VIT) may be associated with a
variety of risk factors, of which the relative importance is unknown. Objective Our aim was to …

Abstract Background The European Academy of Allergy and Clinical Immunology (EAACI) is
developing guidelines for allergen immunotherapy (AIT) for the management of allergic …

The impact on health‐related quality of life (HRQL) plays a key role for patients suffering
from allergies and anaphylaxis. In this narrative review we review the HRQL in allergic …

Background Treatment failure during venom immunotherapy (VIT) may be associated with a
variety of risk factors. Objective Our aim was to evaluate the association of baseline serum …